Praxis Precision Medicines Inc.
Praxis Precision Medicines Announces Financial Results and Strategic Partnerships
Summary
Praxis Precision Medicines, Inc. reported its fourth quarter and full-year 2023 financial results, showcasing significant advancements in its clinical programs and a strong financial position. The company highlighted progress in its Phase 3 Essential3 program for essential tremor, with over 3,000 referrals meeting eligibility criteria. Additionally, Praxis announced a licensing partnership with Tenacia Biotechnology for the development and commercialization of ulixacaltamide in Greater China, with potential consideration of over $275 million. The company also completed a public offering, extending its cash runway into 2026.
Profitelligence Alerts
Get alerts for PRAX
Be first to know when Praxis Precision Medicines Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc. operates within the biopharmaceutical sector, focusing on the development of treatments for central nervous system (CNS) disorders. The company's primary objective is to address unmet medical needs by leveraging their extensive research in genetics, the neurobiology of CNS disorders, and translational science. Praxis Precision Medicines is rapidly carving out a niche in the healthcare field by targeting illnesses such as epilepsy, movement disorders, and psychiatric conditions, which impact millions of individuals globally. Their innovative pipeline includes a variety of therapeutic candidates designed to modulate specific neural pathways that are believed to be core to CNS dysregulation. As an emerging leader in the biopharma industry, Praxis Precision Medicines plays a crucial role in advancing CNS treatment paradigms, working to improve quality of life for patients and expand the possibilities of personalized medicine through cutting-edge science.
Official SEC Documents
Advertisement